| 32.26 0.05 (0.16%) | 04-26 15:14 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 41.35 | 1-year : | 44.48 |
| Resists | First : | 35.4 | Second : | 38.09 |
| Pivot price | 32.84  |
|||
| Supports | First : | 31.05 | Second : | 25.84 |
| MAs | MA(5) : | 32.49 |
MA(20) : | 33.36 |
| MA(100) : | 36.61  |
MA(250) : | 36.31 |
|
| MACD | MACD : | -1 |
Signal : | -1.1 |
| %K %D | K(14,3) : | 28.2 |
D(3) : | 30.1 |
| RSI | RSI(14): 38 |
|||
| 52-week | High : | 46.4 | Low : | 26.05 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ SMTI ] has closed above bottom band by 31.4%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 2 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 33.03 - 33.35 | 33.35 - 33.54 |
| Low: | 30.86 - 31.27 | 31.27 - 31.52 |
| Close: | 31.74 - 32.41 | 32.41 - 32.82 |
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako¯s Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako¯s Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako¯s Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Thu, 18 Apr 2024
Sanara MedTech Inc. Announces $55 Million Debt Facility - GlobeNewswire
Thu, 18 Apr 2024
Sanara Medtech Inc. Announces $55 Million Debt Facility - Marketscreener.com
Wed, 17 Apr 2024
Sanara MedTech (NASDAQ:SMTI) Shares Down 0.2% - MarketBeat
Fri, 29 Mar 2024
Sanara MedTech Inc. (NASDAQ:SMTI) Q4 2023 Earnings Call Transcript - Yahoo Finance
Tue, 26 Mar 2024
Sanara MedTech Inc. (SMTI) Q4 2023 Earnings Call Transcript - Seeking Alpha
Mon, 25 Mar 2024
Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2023 Results - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Instruments & Supplies
|
|
| Shares Out | 9 (M) |
| Shares Float | 3 (M) |
| Held by Insiders | 60.5 (%) |
| Held by Institutions | 8.4 (%) |
| Shares Short | 143 (K) |
| Shares Short P.Month | 144 (K) |
| EPS | -0.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.25 |
| Profit Margin | -6.7 % |
| Operating Margin | -12.4 % |
| Return on Assets (ttm) | -7.1 % |
| Return on Equity (ttm) | -10.3 % |
| Qtrly Rev. Growth | 15.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.53 |
| EBITDA (p.s.) | -0.47 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -62.08 |
| PEG Ratio | 0 |
| Price to Book value | 6.14 |
| Price to Sales | 4.28 |
| Price to Cash Flow | -85.62 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|